Survival rates are higher for patients whose cancer is detected at an early stage. Current technology is not sensitive enough to non-invasively detect early stages of tumor growth.
BioMark offers a robust platform for oncology from diagnostics to therapeutics. The company is conducting a multi site phase lll clinical trials on it's diagnostic technology while conducting toxicity and safety tests on it's antibody based anti cancer drugs. (LSBC)
Member Since: 2014